LEXICON PHARMACEUTICAL

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

26 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in December Investor Conferences

25 Nov 2024 16:15:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: LEXICON PHARMACEUTICALS INC. - COMMON STOCK

22 Nov 2024 09:45:08 By NetDania Notify

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

22 Nov 2024 07:32:16 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: LEXICON PHARMACEUTICALS INC. - COMMON STOCK

21 Nov 2024 10:19:30 By NetDania Notify

Lexicon Appoints Ivan H. Cheung to Board of Directors

20 Nov 2024 16:05:47 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: LEXICON PHARMACEUTICALS INC. - COMMON STOCK

20 Nov 2024 09:58:26 By NetDania Notify

NetDania - New 12 months Low: LEXICON PHARMACEUTICALS INC. - COMMON STOCK

19 Nov 2024 09:45:33 By NetDania Notify

NetDania - New 12 months Low: LEXICON PHARMACEUTICALS INC. - COMMON STOCK

18 Nov 2024 09:46:19 By NetDania Notify

NetDania - New 12 months Low: LEXICON PHARMACEUTICALS INC. - COMMON STOCK

15 Nov 2024 09:51:39 By NetDania Notify

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago

14 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

12 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

06 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

05 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

05 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

04 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

31 Oct 2024 18:54:54 By Nasdaq GlobeNewswire

New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024

23 Oct 2024 09:00:00 By Nasdaq GlobeNewswire

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

22 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

16 Oct 2024 16:35:00 By Nasdaq GlobeNewswire